KRAS and neoplasm: Tumour cells with BRAF (most frequently BRAFV600E) or KRAS mutations are addicted to MEK1/2 (MAPK or ERK Kinase)–ERK1/2 (extracellular signal-regulated kinase) signalling for their proliferation, survival and other malignant properties.